A randomised crossover design study comparing the pharmacokinetics and pharmacodynamics of two single oral doses of aspirin (75 mg v150mg) in pregnant women at risk of pre-eclampsia.

Figure 1: Patient flow diagram



Table 1. Demographic features of study group.

Baseline characteristics		Median (IQR) or numbers (%)
Age		30 (28-33.3)
Height (cm)		165 (158.5-170.5)
Weight (kg)		81.1 (66.8-92.8)
Body mass index (kg/m^2)		30.5 (26.6-33.25)
Gestational age (weeks)		13.7 (13.1-14.2)
Parity		1 (0-1)
Ethnicity;	White British	12 (85.7%)
	Asian (Pakistani)	1 (7.14%)
	Mixed	1 (7.14%)
Risk factors for PE;	Hypertensive disease in previous pregnancy	6 (42.8%)
	Essential hypertension with or without other risk factors	4 (28.6%)
	Combination of moderate risk factors	4 (28.6%)

Data represented as median (IQR) or numbers (%).

Table 2: Pharmacokinetic characteristics of salicylic acid from two doses.

	Median	IQR (Q1- Q3)	p
SA baseline first dose (µg/ml)	0.006	0.002 (0.005-0.007)	
SA baseline second dose (µg/ml)	0.006	0.006 (0.004-0.01)	
SA baseline 1st vs 2nd			0.342
SA baseline 75 mg (µg/ml)	0.006	0.004 (0.005-0.009)	
SA baseline 150 mg (µg/ml)	0.007	0.003 (0.005-0.008)	
SA baseline 75 vs 150			0.561
SA AUC_{0-19} 75 mg (µg *h/ml)	6.8	2.18 (6.14-8.32)	
SA AUC_{0-19} 150 mg (µg *h/ml)	16.68	4.08 (15.19-19.27)	
SA AUC_{0-19} 75 mg vs 150 mg			<0.001
SA C_{max} 75 mg (µg/ml)	1.56	0.47 (1.33-1.8)	
SA C_{max} 150 mg (µg/ml)	3.03	0.71 (2.82-3.53)	
SA C_{max} 75 mg vs 150 mg			<0.001
t1/2 75 mg (hour)	0.02	0.01 (0.02-0.03)	
t1/2 150 mg (hour)	0.03	0.01 (0.02-0.03)	
t1/2 75 mg vs 150 mg			0.073

Table S: $TbxB_2$ characteristics of salicylic acid from two doses

	Median	IQR (Q1- Q3)	P value
$TbxB_2$ baseline first dose (ng/ml)	17.48	47.15 (4.42-51.57)	
$TbxB_2$ baseline second dose (ng/ml)	15.05	38.35 (3-41.35)	
$TbxB_2$ baseline 1st vs 2nd			0.47
$TbxB_2$ baseline 75 mg (ng/ml)	18.98	47.22 (4.35- 51.57)	
$TbxB_2$ baseline 150 mg (ng/ml)	14.43	28.223 (3.79 -32.02)	
$TbxB_2$ baseline 75 vs 150			0.177
$TbxB_2$ AUC_{0-19} 75 mg (ng *h/ml)	102.94	130.62 (21.19- 151.81)	
$TbxB_2$ AUC_{0-19} 150 mg (ng *h/ml)	18.9	36.28 (7.67- 43.95)	
$TbxB_2$ AUC_{0-19} 75 mg vs 150 mg			<0.001
Average reduction 75 mg (%) 1-3 h	74.9	24.68 (65.98- 90.66)	
Average reduction 150 mg (%) 1-3 h	92.86	9.42 (87.6- 97.02)	
Average reduction 75 vs 150 mg 1-3 h			0.011
Normalised Reduction 75 mg (2-4h) (%)	84.76	(77.33-92.31)	
Normalised Reduction 150 mg (2-4h) (%)	95.67	(92.55-97.29	
Normalised Reduction 75 vs 150 mg (2-4h)	91.72	(83.79-97-52)	0.007
Max reduction within first 4 hours 75 mg (%)	96.76	(96-98.9)	
Max reduction within first 4 hours 150 mg (%)			

There were no adverse events associated with this study